Cerity Partners
RGNX icon

Cerity Partners’s Regenxbio RGNX Stock Holding History

Cerity Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$571K Sell
47,643
-10,734
-18% -$89.1K ﹤0.01% 2347
2026
Q1 		$489K Sell
58,377
-13,111
-18% -$138K ﹤0.01% 2302
2025
Q4 		$1.03M Buy
71,488
+6,211
+10% +$77.4K ﹤0.01% 1707
2025
Q3 		$630K Buy
65,277
+18,736
+40% +$166K ﹤0.01% 1840
2025
Q2 		$382K Buy
46,541
+14,695
+46% +$123K ﹤0.01% 2019
2025
Q1 		$228K Buy
+31,846
New +$237K ﹤0.01% 2155

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Cerity Partners's RGNX Position: Q2 2026 in Review

Cerity Partners reduced its Regenxbio (RGNX) stake by 18% in Q2 2026, selling an estimated $89.1K and leaving 47,643 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Cerity Partners first reported a position in RGNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.03M in Q4 2025. 152 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Cerity Partners held 47,643 shares of Regenxbio worth $571K as of Q2 2026.
  • Cerity Partners sold 10,734 Regenxbio shares in Q2 2026, an estimated $89.1K.
  • Regenxbio made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2347 holding.
  • Cerity Partners first reported a position in Regenxbio in Q1 2025 and has held it in 6 quarters since.
  • Cerity Partners's Regenxbio position peaked at $1.03M in Q4 2025.
  • 152 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.